Amryt Pharma Share Discussion Threads

[papillon] 13/6/2019 21:11

Before he deletes them!

mdalos1 - 13 Jun 2019 - 18:59:43 - 4567 of 4568
Amryt Pharma - AMYT
You happy with losing 66% of your large holding when the time comes then ABC-123 ?
That sounds like a "large" 66% to me !!
mdalos1 - 13 Jun 2019 - 18:02:04 - 4565 of 4568
Amryt Pharma - AMYT
Another poor performance (worsening) to Dec 2018
6-12 months of the same and it would be raising large amounts via the begging bowl again.
Conveniently the proposed takeover/acquisition/merger/reverse takeover will fill that begging bowl nicely but with existing UK AIM PIs diluted significantly.

Expecting a further "Business Transformation" plan to be announced beyond the Business re-entering Markets.

I think we could get seriously shafted
:-(

[alphabravo321] 13/6/2019 18:45

I am really looking forward to the re listing, the management have done all they said they would do albeit a bit slower than we had hoped, this could turn our very well in late 2019 or 2020, I am a large holder here and i tend on staying to see how this all shapes up... I only invest in shares where the management have serious financial skin in the game as the guys do here...I have read the annual report and am happy with the progress to date, slow and steady wins the race

[papillon] 12/6/2019 22:35

AMYT for me was always a punt on the outcome of the phase III trial for AP101. Existing AMYT shareholders have been promised US$85m if AP101 comes up trumps. That sum is independent of the share price of the relisted AMYT.

PS I don't believe mdalos's analysis and figures are correct. AMYT have stated (RNS dated 21/5/2019) that the US$60m placing price will be at a 20% discount to the ESTIMATED value of AMYT prior to the completion of the acquisition of Aegerion. That estimated value is US$120m according to that RNS. Hence, unless AMYT are telling porkies, the consolidation will not affect the increase in value of our AMYT shares on relisting. As usual mdalos twists the facts to suit his agenda. Basically he's a compulsive liar who deletes his posts. Only time will tell if AMYT are also being economical with the truth with regard to their RNS dated 21/5/2019.

I'm hoping that the action of the AMYT share price on relisting will be similar to what has happened at VENN. The placing price was significantly higher than the suspension price. This led to a big jump up in the VENN share price when it relisted yesterday. The VENN share price was suspended around 2.6p, but the recent placing was priced at 5.6p and the share price closed today at 5.3p. That's around double the suspension price. How they managed to get a placing away at 5.6p baffles me (and probably baffles mdalos!), but they did (there was no share consolidation with VENN). I'm hopeful that similar happens with AMYT and that my £2.8k becomes worth over £5k when AMYT relists.

PPS. AMYT had to consolidate to get the share price higher because of the proposed Nasdaq listing. This consolidation should ensure the placing is priced north of a dollar.

[chica1] 12/6/2019 20:18

Interesting it seems Marc Summeray Amryt's CMO is being sued for fraud by the state of Massachusetts?

[bermudashorts] 12/6/2019 20:10

Exactly Waterloo.

[waterloo01] 12/6/2019 18:49

Actually you also need to add in the shares and the assets/market cap into the equation of the take over. Te market cap of the two combined will be a lot higher, as will the shares issued to make the acquisition.

Lots still unknown

[dlm2602] 12/6/2019 18:15

mdalos1,

That's just wrong. As you like examples, this is what I believe will occur

Before consolidation:
Amryt has 276m shares in circulation, share price is 12.5p = market Cap = £34.5

After 6:1 consolidation:
Amryt has 276/6 = 46m shares in circulation, market cap remains at £34.5 as assets still the same, thus new consolidated share price = £34.5m / 46m = 75p

Whatever happens to Amryt after the deal concludes will be referenced from a starting position of 75p

[papillon] 12/6/2019 13:58

I'm assuming the US$85m promised to existing AMYT shareholders (in cash, or shares) if AP101 is a "rip roaring" success will be to AMYT shareholders on the register at the 21/5/2019 suspension. It doesn't make sense otherwise since once the new company relists it will include new shareholders.

[papillon] 12/6/2019 13:49

So for every 6 shares held pre suspension we will end up with ONE share (excluding fractions). That means the relisted share price will need to be 74.250p to equal the suspension price of 12.375p.

The share price for the US$60m placing was forecast to be 27.5p based on estimated value for AMYT of US$120m post acquisition (RNS 21/5/2019). That means they intend to place shares at 165p to account for the 1 for 6 consolidation. I'LL BELIEVE IT WHEN I SEE IT!!!! I'm DEFINITELY NOT counting my chickens until they have hatched!!!!

Meanwhile there is nothing I can do about it until the shares relist (hopefully!) in October.

[papillon] 12/6/2019 13:14

Seeing he'll soon delete it I've taken the liberty of copying and pasting mdalos's post. Make of it what you will

mdalos1 - 12 Jun 2019 - 09:14:29 - 4549 of 4551
Amryt Pharma - AMYT


Share consolidation, reduction in shares in issue BUT company funds being used to take them out of circulation, ultimately we'll need to try to associate the approx. 16% of shares in issue left in circulation with the dubious numbers already being touted by the takeover/acquisition/merger/reverse takeover activities to fathom where we might stand when the Business returns to Market !!!!

50% chance we're going to lose out
50% chance of a one-time, brief opportunity to benefit

[dlm2602] 12/6/2019 10:27

mdalos1

I don't share your pessimism here. This is standard practice and will not affect the cash in the business at all other than the administrative expense in doing the exercise. The $ value attributed to Amryt in the deal with Aegerion remains the same.